GERN vs VRTX · rev $109.3M vs P/E 30, rev $3.33B
Geron Corporation (GERN) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
Geron Corporation (GERN) is a biotechnology company listed on US.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US. It is led by Reshma Kewalramani FASN, M.D..
Latest reported GERN revenue for 2026-06-30 was $109.3M. Net income was -$20.3M. GERN currently screens at market cap $878.9M.
Latest reported VRTX revenue for 2026-06-30 was $3.33B. Net income was $1.10B. Revenue was up 11.6% from 2026-03-31 to 2026-06-30. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
GERN currently screens at market cap $878.9M. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the GERN and VRTX stock pages for the full models.
Not investment advice.